Cargando…
Outcome of adalimumab monotherapy in paediatric non-infectious uveitis
BACKGROUND: Adalimumab in combination with other disease-modifying antirheumatic drugs (DMARD) such as methotrexate has a proven efficacy in the management of paediatric non-infectious uveitis. However, many children experience significant intolerance to methotrexate while on this combination, leavi...
Autores principales: | Al-Julandani, DA, Bagri, NK, Tsang, N, Clarke, S, Upadhyay, A, Guly, C, Ramanan, AV |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983208/ https://www.ncbi.nlm.nih.gov/pubmed/36864437 http://dx.doi.org/10.1186/s12969-023-00794-y |
Ejemplares similares
-
Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy
por: Cann, Megan, et al.
Publicado: (2018) -
Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis
por: Erckens, R. J., et al.
Publicado: (2011) -
Clinical benefits and potential risks of adalimumab in non‐JIA chronic paediatric uveitis
por: Kouwenberg, Carlyn V., et al.
Publicado: (2021) -
Early administration of adalimumab for paediatric uveitis due to Behçet’s disease
por: Hiyama, Tomona, et al.
Publicado: (2019) -
Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)
por: Ramanan, Athimalaipet V., et al.
Publicado: (2021)